Skip to main content
eBioMedicine logoLink to eBioMedicine
. 2024 Sep 24;108:105371. doi: 10.1016/j.ebiom.2024.105371

Corrigendum to “The significance of recurrent de novo amino acid substitutions that emerged during chronic SARS-CoV-2 infection: an observational study” [eBioMedicine, 2024;107:105273]

Jonathan Daniel Ip a, Wing-Ming Chu b, Wan-Mui Chan a, Allen Wing-Ho Chu a,c, Rhoda Cheuk-Ying Leung a,c, Qi Peng d, Anthony Raymond Tam b, Brian Pui-Chun Chan a, Jian-Piao Cai a, Kwok-Yung Yuen a,c,e,f, Kin-Hang Kok a,c, Yi Shi d, Ivan Fan-Ngai Hung b,f,g, Kelvin Kai-Wang To a,c,e,f,
PMCID: PMC11462265  PMID: 39321502

The authors have found that the published version of the article contained an error in Figure 4 and Supplementary Table S4. We have mislabelled the patients P31, P32, and P33 as P29, P30, and P31, respectively. These mistakes affected the patient labellings for the DNS at NSP9 35, Spike 440, and Spike 450. The original and corrected figures and tables are shown below. The errors were introduced during drafting of the manuscript, and do not affect the results, interpretation, and conclusion. This update does not affect the main text, and other parts of the publication. The authors apologize for any inconvenience caused by these errors.

Original version:

graphic file with name fx1.jpg

Corrected version:

graphic file with name fx2.jpg

The original and corrected patient numbers for the affected protein DNS residue in Supplementary Table S4:

Protein Amino acid residue Original patient number Corrected patient number
NSP3 977 P30 P32
NSP9 35 P29 P31
NSP9 35 P30 P32
NSP9 35 P31 P33
S 440 P31 P33
S 450 P30 P32
S 450 P31 P33

The corrected Supplementary Table S4 is shown below.

Protein Amino acid residue VOC/VOI with this substitution as lineage-defining mutation (Date of designationa) Patient number 1st sequence with the respective substitutionc
NSP3 977 Gamma (VOC: 2021-01-11) P4 July 2022
P13 September 2021
P32 October 2022
NSP5 90 Beta (VOC: 2020-12-18) P9 September 2021
P10 2020
P23 March 2021
NSP9 35 EG.5 (VOI: 2023-08-09)
BA.2.86 (VOI: 2023-11-21)
JN.1 (VOI: 2023-12-18)
P9 September 2021
P31 November 2022
P32 July 2022
P33 October 2022
NSP12 671 Delta (VOC: 2021-05-11)
XBB.1.5 (VOI: 2023-01-11)
XBB.1.16 (VOI: 2023-04-17)
P4 August 2022
P9 September 2021
P31 February 2023
S 484 Beta (VOC: 2020-12-18)
Gamma (VOC: 2021-01-11)
Omicron (VOC: 2021-11-26)
Eta (VOI: 2021-03-17)
Theta (VOI: 2021-03-24)
Kappa (VOI: 2021-04-04)
Mu (VOI: 2021-08-30)
Zeta (VOI: 2021-09-17)
XBB.1.5 (VOI: 2023-01-11)
XBB.1.16 (VOI: 2023-04-17)
EG.5 (VOI: 2023-08-09)
BA.2.86 (VOI: 2023-11-21)
JN.1 (VOI: 2023-12-18)
P1 June 2020
P2 June 2021
P5 October 2020
P6 February 2021
P8 May 2020
P12 November 2020
P13 June 2021
P22 July 2020
P24 February 2021
P26 June 2021
490 Lambda (VOI: 2021-06-14)
XBB.1.5 (VOI: 2023-01-11)
XBB.1.16 (VOI: 2023-04-17)
EG.5 (VOI: 2023-08-09)
P2 June 2021
P5 December 2020
P7 December 2021
P8 May 2020
P9 September 2021
P12 November 2020
P18 N/A
95 Iota (VOI: 2021-03-24)
Mu (VOI: 2021-08-30)
Omicron (VOC: 2021-11-26)b
P2 June 2021
P6 October 2021
P7 November 2021
P17 November 2021
P18 N/A
493 Omicron (VOC: 2021-11-26)e P1 August 2020
P7 June 2021
P25 May 2021
P26 March 2021
13 Epsilon (VOI: 2021-03-05) P2 June 2021
P3 August 2020
P8 May 2020
417 Beta (VOC: 2020-12-18)
Gamma (VOC: 2021-01-11)
Omicron (VOC: 2021-11-26)d
XBB.1.5 (VOI: 2023-01-11)
XBB.1.16 (VOI: 2023-04-17)
EG.5 (VOI: 2023-08-09)
BA.2.86 (VOI: 2023-11-21)
JN.1 (VOI: 2023-12-18)
P5 December 2020
P21 July 2022
P24 October 2022
440 Omicron (VOC: 2021-11-26)d P1 September 2020
P28 January 2021
P33 November 2022
450 BA.2.86 (VOI: 2023-11-21)
JN.1 (VOI: 2023-12-18)
P9 September 2021
P32 September 2022
P33 October 2022
655 Gamma (VOC: 2021-01-11)
Omicron (VOC: 2021-11-26)
XBB.1.5 (VOI: 2023-01-11)
XBB.1.16 (VOI: 2023-04-17)
EG.5 (VOI: 2023-08-09)
BA.2.86 (VOI: 2023-11-21)
JN.1 (VOI: 2023-12-18)
P7 December 2021
P10 2020
P21 June 2022
M 82 Eta (VOI: 2021-03-17)
Delta (VOI: 2021-04-04, VOC: 2021-05-11)
Kappa (VOI: 2021-04-04)
P2 June 2021
P7 March 2021
P10 2020
P26 August 2021

Abbreviations: F, female; M, male; VOC, variants of concern; VOI, variants of interest.

a

The dates of designation for the VOI and VOC were referenced from WHO's “Historical working definitions and primary actions for SARS-CoV-2 variants” document: https://www.who.int/publications/m/item/historical-working-definitions-and-primary-actions-for-sars-cov-2-variants and https://www.who.int/activities/tracking-SARS-CoV-2-variants/previously-circulating-vois.

b

Only in BA.1.

c

The dates that appear before the designation of the corresponding VOC/VOI by the WHO are Indicated in bold face.

d

Only in BA.2, BA.4, and BA.5.

e

Only BA.1 and BA.2.


Articles from eBioMedicine are provided here courtesy of Elsevier

RESOURCES